Skip to main content
. Author manuscript; available in PMC: 2020 Jun 10.
Published in final edited form as: Int Forum Allergy Rhinol. 2018 Feb;8(2):108–352. doi: 10.1002/alr.22073

TABLE X.A.4-4.

Evidence for omalizumab for the treatment of asthma in the context of coexistent allergic rhinitis

Study Year LOE Study design Study groups Clinical endpoint Conclusion
Kopp et al.1403 2009 1b DBRCT AR and seasonal asthma. All patients received SCIT. (n = 140):
  1. SCIT + omalizumab;

  2. SCIT + placebo

AR and asthma symptoms, rescue medication use, PEF, patient and provider GETE, asthma symptoms by ACQ, disease-specific QOL by AQLQ and RQLQ, PFTs Omalizumab addition to SCIT: reduced symptom severity, improved QOL by ACQ and AQLQ. No difference in rescue medication use. No difference in FEV1 or mean PEF.
Vignola et al.1820 2004 1b DBRCT Moderate-to-severe persistent AR and allergic asthma (n = 405):
  1. Omalizumab;

  2. Placebo

Asthma exacerbations, disease-specific QOL by AQLQ and RQLQ, rescue medication use, symptom scores, patient and investigator GETE, inhaled corticosteroid use, FEV1, FVC, and morning PEF Omalizumab: reduced asthma exacerbations; increased AQLQ and RQLQ; reduced asthma symptoms; increased FEV1, FVC, and PEF. No difference in β-agonist use.

ACQ = Asthma Control Questionnaire; AQLQ = Asthma Quality of Life Questionnaire; AR = allergic rhinitis; DBRCT = double-blind randomized controlled trial; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GETE = Global Evaluation of Treatment Effectiveness; LOE = level of evidence; PEF = peak expiratory flow; PFT = pulmonary function test; QOL = quality of life; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SCIT = subcutaneous immunotherapy.

HHS Vulnerability Disclosure